Company Monitoring Page for Sarepta

job ratings for Sarepta

11/07/24
industry:
Biotechnology
company:
Sarepta
job rating:
2
PPMO down. This means realigning and likely streamlining. Prepare CV

latest headlines for company on cafepharma

Sarepta touts clean data for commercial grade Duchenne gene therapy, clearing key hurdle to PhIII
Endpoints
Tue, 05/18/21 - 11:11 am
Tags:
Sarepta, Duchenne Muscular Dystrophy, clinical trials, gene therapy
Mark Your Calendar For February PDUFA Dates
Yahoo/Benzinga
Sun, 01/31/21 - 10:18 pm
Tags:
FDA, Adamas Pharmaceuticals, Gocovri, Mallinckrodt, StrataGraft, Regeneron, evinacumab, Sanofi, Sarepta, TG Therapeutics
Sarepta collects half a billion in follow-on
BioCentury
Thu, 11/8/18 - 08:46 pm
Tags:
Sarepta
3 Biotech Stocks That Could Soar in September
Motley Fool
Sun, 08/27/17 - 06:26 pm
Tags:
biotech, fitusiran, Alnylam, PTC Therapeutics, Translarna, Sarepta, Exondys 51
Sarepta May Have More Upside After Sales Data
Seeking Alpha
Thu, 01/19/17 - 11:47 am
Tags:
Sarepta, Duchenne Muscular Dystrophy, Exondys 51, eteplirsen
Will Insurers Pay For Sarepta’s DMD Drug?
Barron's
Thu, 12/15/16 - 10:05 am
Tags:
Sarepta, Duchenne Muscular Dystrophy, Exondys 51, Medicaid, payers, insurers
3 Biotechs That Just Announced Successful Phase 2 Trials
24/7 Wall St
Sun, 06/12/16 - 10:03 pm
Tags:
clinical trials, TEV-1845, Teva Pharmaceutical, migraines, Sarepta, eteplirsen, Duchenne Muscular Dystrophy
Sarepta shares soar on FDA voting questions
CNBC
Fri, 04/22/16 - 09:38 pm
Tags:
Sarepta, FDA, eteplirsen, Duchenne Muscular Dystrophy
Sarepta, Biomarin vie for DMD approval, priority review voucher
BioPharma Dive
Mon, 08/24/15 - 11:47 am
Tags:
Sarepta, Biomarin, Duchenne Muscular Dystrophy, FDA, priority review, review vouchers
Sarepta Earnings Preview: 3 Things to Watch For
Investopedia
Tue, 05/5/15 - 08:42 am
Tags:
Sarepta, earnings
Sarepta jumps on fresh optimism for an early approval
Fierce Biotech
Thu, 01/16/14 - 11:34 am
Tags:
Sarepta, Duchenne Muscular Dystrophy, eteplirsen
Amarin, Sarepta And Vanda: Teachable Moments In Biotech
Seeking Alpha
Sun, 11/17/13 - 12:13 pm
Tags:
Amarin, Sarepta, Vanda
7 Disruptive Drugs for the Next Decade
Motley Fool
Wed, 10/9/13 - 10:42 pm
Tags:
Tecfidera, Biogen Idec, Bristol-Myers Squibb, Eliquis, Pfizer, Roche, Kadcyla, Immunogen, sofosbuvir, Gilead, ibrutinib, Pharmacyclics, Sarepta, eteplirsen, LX4211, Lexicon Pharmaceuticals
3 Key Points From Sarepta's Eteplirsen Study Update (And They're Positive)
TheStreet.com
Thu, 09/26/13 - 10:35 am
Tags:
Sarepta, eteplirsen, Genentech, GSK, Duchenne Muscular Dystrophy
Four Promising Biotech Stocks With Upcoming Catalysts
Minyanville
Thu, 08/22/13 - 10:05 am
Tags:
GSK, Sarepta, Gilead, sofosbuvir, SGX203, SGX942, Soligenix, drisapersen
Sarepta shares jump after disappointing test for rival drug
Reuters
Fri, 08/16/13 - 10:33 am
Tags:
Prosensa, drisapersen, Duchenne Muscular Dystrophy, GSK, Sarepta, eteplirsen
The Best- And Worst-Performing Biotech Stocks July 19 To July 26
Forbes
Mon, 07/29/13 - 12:27 pm
Tags:
TearLab, Array Biopharma, Furiex Pharmaceuticals, InterMune, Prosensa, Boston Scientific, Orexigen, Momenta, Ironwood, INSYS Therapeutics, Sequenom, OncoMed, Abraxis, Sarepta, Epizyme, Tesaro, Synta Pharmaceuticals, Bluebird Bio, Exelixis, Lexicon Pharmaceuticals, Intercept Pharma, GTx
Biotech Stocks Under Pressures, Focus On IPOs
Property Mentor Group
Fri, 07/26/13 - 11:37 am
Tags:
IPOs, Sequenom, Invovio, Aeterna Zentaris, Sarepta, InterMune, Cryolife, BiogenIdec, Boston Scientific, Varian Medical, Warner Chilcott
Sarepta To Seek Early U.S. Approval For Muscular Dystrophy Drug
TheStreet.com
Wed, 07/24/13 - 09:54 am
Tags:
Sarepta, FDA, Duchenne Muscular Dystrophy, eteplirsen
Is The DMD Market Becoming Too Crowded?
Motley Fool
Tue, 07/9/13 - 05:14 pm
Tags:
Duchenne Muscular Dystrophy, Sarepta, eteplirsen, drisapersen, GSK, PTC Therapeutics

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.